Pfizer’s pregabalin litigation: the latest twist

15-02-2023

Darren Smyth

Pfizer’s pregabalin litigation: the latest twist

Molly Woodward / Shutterstock.com

The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.

On February 1 2023, the Court of Appeal of England and Wales handed down its decision in the latest instalment of the ongoing litigation concerning Pfizer’s product Lyrica (pregabalin), which first emerged back in 2014.

This decision leaves NHS Scotland open to continue to push for damages from Pfizer, although most NHS trusts have now settled their claims.

The background


EIP, Pfizer, pregabalin, litigation, NHS, generic drug makers, Court of Appeal of England and Wales, infringement, injunction, Allergan, Dr Reddys, Mylan

LSIPR